Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229–63. https://doi.org/10.3322/caac.21834.

Article  PubMed  Google Scholar 

Jazieh K, Khorrami M, Saad A, Gad M, Gupta A, Patil P, et al. Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab. J Immunother Cancer. 2022. https://doi.org/10.1136/jitc-2021-003778.

Article  PubMed  PubMed Central  Google Scholar 

Lee JM, McNamee CJ, Toloza E, Negrao MV, Lin J, Shum E, et al. Neoadjuvant targeted therapy in resectable NSCLC: current and future perspectives. J Thorac Oncol. 2023;18:1458–77. https://doi.org/10.1016/j.jtho.2023.07.006.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Andreas S, Chouaid C, Danson S, Siakpere O, Benjamin L, Ehness R, et al. Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: a retrospective observational study (LuCaBIS). Lung Cancer. 2018;124:298–309. https://doi.org/10.1016/j.lungcan.2018.06.007.

Article  PubMed  Google Scholar 

Group NM-aC. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet (London England). 2014;383:1561–71. https://doi.org/10.1016/s0140-6736(13)62159-5.

Article  Google Scholar 

Zhou Q, Pan Y, Yang X, Zhao Y, Han G, Pang Q, et al. Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III non-small-cell lung cancer: A proof-of-concept, phase 2 trial. Cancer Cell. 2024;42:1258–e672. https://doi.org/10.1016/j.ccell.2024.05.024.

Article  CAS  PubMed  Google Scholar 

Topalian SL, Taube JM, Pardoll DM. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science (New York, NY). 2020. https://doi.org/10.1126/science.aax0182.

Article  Google Scholar 

Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med. 2018;378:1976–86. https://doi.org/10.1056/NEJMoa1716078.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al. Neoadjuvant Nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386:1973–85. https://doi.org/10.1056/NEJMoa2202170.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Keam B, Im SA, Koh Y, Han SW, Oh DY, Cho N, et al. Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy. BMC Cancer. 2011;11:452. https://doi.org/10.1186/1471-2407-11-452.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Deng Y, Zhang X, Hu F, Lan X. Quantitative (18)F-FDG PET/CT model for predicting pathological complete response to neoadjuvant immunochemotherapy in NSCLC: comparison with RECIST 1.1 and PERCIST. Eur J Nucl Med Mol Imaging. 2025;52:4806–19. https://doi.org/10.1007/s00259-025-07342-8.

Article  CAS  PubMed  Google Scholar 

Fischer B, Lassen U, Mortensen J, Larsen S, Loft A, Bertelsen A, et al. Preoperative staging of lung cancer with combined PET-CT. N Engl J Med. 2009;361:32–9. https://doi.org/10.1056/NEJMoa0900043.

Article  CAS  PubMed  Google Scholar 

Jiang ZP, Shan HM, Zhu HY, Cheng Y, Lu KY, Fan W, et al. The prognostic value of baseline 18 F-FDG PET/CT in stage IV non-small cell lung cancer patients receiving osimertinib treatment. Clin Nucl Med. 2025;50:e516–22. https://doi.org/10.1097/rlu.0000000000006039.

Article  PubMed  Google Scholar 

Cheng Y, Chen Z-y, Huang J-j, Shao D. Efficacy evaluation of neoadjuvant immunotherapy plus chemotherapy for non-small-cell lung cancer: comparison of PET/CT with postoperative pathology. Eur Radiol. 2023;33:6625–35. https://doi.org/10.1007/s00330-023-09922-4.

Article  CAS  PubMed  Google Scholar 

Hellmann MD, Chaft JE, William WN Jr., Rusch V, Pisters KM, Kalhor N, et al. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol. 2014;15:e42–50. https://doi.org/10.1016/s1470-2045(13)70334-6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Skougaard K, Nielsen D, Jensen BV, Hendel HW. Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab. J nuclear medicine: official publication Soc Nuclear Med. 2013;54:1026–31. https://doi.org/10.2967/jnumed.112.111757.

Article  CAS  Google Scholar 

Uramoto H, Tanaka F. Recurrence after surgery in patients with NSCLC. Transl Lung Cancer Res. 2014;3:242–9. https://doi.org/10.3978/j.issn.2218-6751.2013.12.05.

Article  PubMed  PubMed Central  Google Scholar 

Uprety D, Mandrekar SJ, Wigle D, Roden AC, Adjei AA. Neoadjuvant immunotherapy for NSCLC: current concepts and future approaches. J Thorac oncology: official publication Int Association Study Lung Cancer. 2020;15:1281–97. https://doi.org/10.1016/j.jtho.2020.05.020.

Article  CAS  Google Scholar 

Godoy LA, Chen J, Ma W, Lally J, Toomey KA, Rajappa P, et al. Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives. Biomark Res. 2023;11:7. https://doi.org/10.1186/s40364-022-00444-7.

Article  PubMed  PubMed Central  Google Scholar 

Fukuda S, Suda K, Hamada A, Tsutani Y. Recent advances in perioperative immunotherapies in lung cancer. Biomolecules. 2023. https://doi.org/10.3390/biom13091377.

Article  PubMed  PubMed Central  Google Scholar 

Blumenthal GM, Bunn PA Jr., Chaft JE, McCoach CE, Perez EA, Scagliotti GV, et al. Current status and future perspectives on neoadjuvant therapy in lung cancer. J Thorac Oncol. 2018;13:1818–31. https://doi.org/10.1016/j.jtho.2018.09.017.

Article  CAS  PubMed  Google Scholar 

Avril S, Muzic RF, Plecha D, Traughber BJ, Vinayak S, Avril N. 18F-FDG PET/CT for monitoring of treatment response in breast cancer. J Nucl Med. 2016;57:S34-9. https://doi.org/10.2967/jnumed.115.157875.

Article  CAS  Google Scholar 

Jiang J, Wang Y, Gao Y, Sugimura H, Minervini F, Uchino J, et al. Neoadjuvant immunotherapy or chemoimmunotherapy in non-small cell lung cancer: a systematic review and meta-analysis. Transl Lung Cancer Res. 2022;11:277–94. https://doi.org/10.21037/tlcr-22-75.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang Z, Wang S, Yang H, Jiang Y, Zhu L, Zheng B, et al. Treatment patterns and clinical outcomes of patients with resectable non-small cell lung cancer receiving neoadjuvant immunochemotherapy: A large-scale, multicenter, real-world study (NeoR-World). J Thorac Cardiovasc Surg. 2024;168:1245–e5817. https://doi.org/10.1016/j.jtcvs.2024.02.006.

Article  PubMed  Google Scholar 

Brunelli A, Hoffman R, Wotton R, Baijal S, Bhatnagar P, Clarke K, et al. Surgical and pathological results following neoadjuvant nivolumab and platinum-based chemotherapy for locally advanced resectable NSCLC: a multicentre real-world series from England. Clin Lung Cancer. 2025;26:253–61. https://doi.org/10.1016/j.cllc.2024.12.010.

Article  CAS  PubMed  Google Scholar 

Mitsudomi T, Ito H, Okada M, Sugawara S, Shio Y, Tomii K, et al. Neoadjuvant nivolumab plus chemotherapy in resectable non-small-cell lung cancer in Japanese patients from CheckMate 816. Cancer Sci. 2024;115:540–54. https://doi.org/10.1111/cas.16030.

Article  CAS  PubMed  Google Scholar 

Kong X, Moran MS, Zhang N, Haffty B, Yang Q. Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients. Eur J Cancer. 2011;47:2084–90. https://doi.org/10.1016/j.ejca.2011.06.014.

Article  PubMed  Google Scholar 

Liu W, Ren S, Yang L, Xiao Y, Zeng C, Chen C, et al. The predictive role of hematologic markers in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy: a retrospective cohort study. Int J Surg. 2023;109:3519–26. https://doi.org/10.1097/js9.0000000000000650.